Invasive Group B Streptococcal Disease Clinical Trial
Official title:
Genetic Susceptibility to Invasive Streptococcal Disease
| Verified date | May 2018 |
| Source | University of Oxford |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Invasive bacterial infection is a dangerous but relatively uncommon disease where bacteria
spread deep into the body causing diseases like blood poisoning ('bacteraemia'), pneumonia,
meningitis and others. The various bacteria of the streptococcus family are an important
cause, often leading patients to require intensive care despite which, for some strains, one
in five patients die. One notable form is called necrotising fasciitis, a condition where
bacteria rapidly spreads through and destroys the layers of tissue just under the skin.
As individuals vary greatly in their risk of developing such serious infections,
investigating how the genome, the inherited blueprint of our bodies, of these patients
differs from that of healthy volunteers can help to explain why the disease develops in some
and not others. For some streptococcal bacteria such as Streptococcus pneumoniae this
approach is already proving successful; for others such as the "Group A" strain
(Streptococcus pyogenes) it has yet to be explored but carries excellent potential.
The investigators have secured the support of the Lee Spark Necrotising Fasciitis Foundation
to recruit from their membership survivors of streptococcal infections and some of their
family members. The investigators will also ask infection specialists from NHS hospitals to
invite patients they have looked after. The investigators also have a small existing
collection. Taking part would involve registering information on a website, discussing the
study on the telephone and then providing us with a sample of saliva from which the
investigators can isolate DNA. The investigators would prepare the sample for analysis of the
genome and compare the patients with both their family and an existing reference collection
from healthy volunteers using technology that reads the DNA code.
Our study will be a first key step in renewing efforts to understand the determinants of
invasive streptococcal infection, which is important for developing better treatments and
vaccines.
| Status | Active, not recruiting |
| Enrollment | 200 |
| Est. completion date | December 2019 |
| Est. primary completion date | December 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Participants for the genetics study are divided into cases/survivors and family members
(relatives and parents). To participate as a survivor, the individual must meet criteria 1A. Their illness can have occurred anytime from birth up until enrolment, providing it happened after 1st January 1980. Family members can only take part if invited to do so by the survivor from their family at the request of the research team. In families in which two or more survivors are identified, all the remaining first- and second-degree relatives of the survivors will be eligible to participate. The recruitment team subdivide those relatives on enrolment into healthy (Criteria 2) or intermediate (Criteria 3) phenotype. In families in which there is only a single survivor, the recruitment team will assess whether the survivor meets criteria 1B. If so the parents of that survivor are eligible to participate if they have a healthy phenotype (Criteria 4). Inclusion Criteria: 1. Cases/Survivors A. All Cases (survivors in pedigree, trio or as simplex case; existing serum samples from Imperial College London collection) - Either of: - Isolation of Streptococcus species from a normally sterile site (e.g. blood, joint fluid, etc.) during an acute illness since 1st January 1980 - Severe clinical presentation - streptococcal toxic shock, necrotising fasciitis, pneumonia, puerperal sepsis, meningitis - since 1st January 1980 plus concurrent Streptococcus species isolated from non-sterile site (e.g. abscess, wound swab, pus) - And: - Admitted to an NHS hospital in England or Wales or Northern Ireland B. Trio case (survivor in trio) - All of: - Meets criteria for 1A - Less than 40 years of age at the time of illness - None of at the time of the illness: heart disease, diabetes mellitus, cancer, steroid use, chronic lung disease, immunocompromise, intravenous drug use and alcoholism - Plus one of: - More than one episode of illness meeting criteria for 1A - Admission to high dependency or intensive care unit - Requirement for surgical procedure (including drainage of abscess or collection) - And: - Both parents alive at time of recruitment 2. Unaffected phenotype family member in multi-case pedigree - All of: - Biological first or second degree relative of a survivor meeting criteria 1A in a family in which two or more members meet those criteria - None of: severe streptococcal illness requiring hospital illness, recurrent tonsillitis or recurrent impetigo (recurrent is defined as more than one episode in two consecutive years) 3. Intermediate phenotype family member in multi-case pedigree - All of: - Biological first or second degree relative of a survivor meeting criteria 1A in a family in which two or more members meet those criteria - History of severe bacterial illness requiring hospital admission, recurrent tonsillitis or recurrent impetigo (recurrent is defined as more than one episode in two consecutive years) 4. Parent in mother-father-child trio - All of: - Biological parent of case meeting criteria for 1B - None of: severe bacterial illness requiring hospital admission, recurrent tonsillitis or recurrent impetigo (recurrent is defined as more than one episode in two consecutive years) Exclusion Criteria: 1. Adults (age > 16 years) unable to consent for themselves. |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | University of Oxford Wellcome Trust Centre for Human Genetics | Oxford | Oxon |
| Lead Sponsor | Collaborator |
|---|---|
| University of Oxford | Imperial College London, Public Health England |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of genetic variants at which cases of invasive streptococcal infection (as defined in inclusion criteria 1) differ from their family members (inclusion criteria 2-4) | This is an observational study comparing genetic data from cases (inclusion criteria 1) vs unaffected family members (inclusion criteria 2-4) and publically available genetic data from health volunteers in existing reference databases (e.g. UK10K - http://www.uk10k.org/). The case's illness (as defined in inclusion criteria 1) may have occurred anytime between 1st January 1980 and enrolment. The outcome is measured by genetic testing using a sample collected on enrolment. There is no follow-up period. | The outcome is measured once by genetic testing using a sample collected on enrolment ('baseline'). There is no follow-up period. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01933646 -
Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China
|
N/A | |
| Recruiting |
NCT02812576 -
Burden of Invasive Group B Streptococcal Disease in Infants and Resistance Surveillance in China
|
N/A |